Research programme: stem cell modulators - Intrexon/Superview Biotechnology

Drug Profile

Research programme: stem cell modulators - Intrexon/Superview Biotechnology

Latest Information Update: 12 Mar 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MediStem Laboratories; Superview Biotechnology
  • Developer Medistem; Superview Biotechnology
  • Class Monoclonal antibodies
  • Mechanism of Action Stem cell modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Unspecified

Most Recent Events

  • 12 Mar 2014 No development reported for Undefined indication (unspecified route)
  • 07 Mar 2014 Medistem has been acquired by Intrexon Corporation
  • 01 Oct 2012 Early research in Undefined indication (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top